150 related articles for article (PubMed ID: 21218817)
1. Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.
Miyamoto Y; Banno Y; Yamashita T; Fujimoto T; Oi S; Moritoh Y; Asakawa T; Kataoka O; Yashiro H; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Sasaki M; Funami M; Amano M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
J Med Chem; 2011 Feb; 54(3):831-50. PubMed ID: 21218817
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.
Miyamoto Y; Banno Y; Yamashita T; Fujimoto T; Oi S; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Amano M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Jan; 19(1):172-85. PubMed ID: 21163664
[TBL] [Abstract][Full Text] [Related]
3. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
5. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
[TBL] [Abstract][Full Text] [Related]
6. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
Madar DJ; Kopecka H; Pireh D; Yong H; Pei Z; Li X; Wiedeman PE; Djuric SW; Von Geldern TW; Fickes MG; Bhagavatula L; McDermott T; Wittenberger S; Richards SJ; Longenecker KL; Stewart KD; Lubben TH; Ballaron SJ; Stashko MA; Long MA; Wells H; Zinker BA; Mika AK; Beno DW; Kempf-Grote AJ; Polakowski J; Segreti J; Reinhart GA; Fryer RM; Sham HL; Trevillyan JM
J Med Chem; 2006 Oct; 49(21):6416-20. PubMed ID: 17034148
[TBL] [Abstract][Full Text] [Related]
8. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors.
Wallace MB; Feng J; Zhang Z; Skene RJ; Shi L; Caster CL; Kassel DB; Xu R; Gwaltney SL
Bioorg Med Chem Lett; 2008 Apr; 18(7):2362-7. PubMed ID: 18346892
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
11. Discovery of β-aminoacyl containing thiazolidine derivatives as potent and selective dipeptidyl peptidase IV inhibitors.
Park WS; Kang SK; Jun MA; Shin MS; Kim KY; Rhee SD; Bae MA; Kim MS; Kim KR; Kang NS; Yoo SE; Lee JO; Song DH; Silinski P; Schneider SE; Ahn JH; Kim SS
Bioorg Med Chem Lett; 2011 Mar; 21(5):1366-70. PubMed ID: 21306895
[TBL] [Abstract][Full Text] [Related]
12. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
[TBL] [Abstract][Full Text] [Related]
13. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
Eckhardt M; Langkopf E; Mark M; Tadayyon M; Thomas L; Nar H; Pfrengle W; Guth B; Lotz R; Sieger P; Fuchs H; Himmelsbach F
J Med Chem; 2007 Dec; 50(26):6450-3. PubMed ID: 18052023
[TBL] [Abstract][Full Text] [Related]
14. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
15. Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554.
Maezaki H; Tawada M; Yamashita T; Banno Y; Miyamoto Y; Yamamoto Y; Ikedo K; Kosaka T; Tsubotani S; Tani A; Asakawa T; Suzuki N; Oi S
Bioorg Med Chem Lett; 2017 Aug; 27(15):3565-3571. PubMed ID: 28579121
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
Zhang Z; Wallace MB; Feng J; Stafford JA; Skene RJ; Shi L; Lee B; Aertgeerts K; Jennings A; Xu R; Kassel DB; Kaldor SW; Navre M; Webb DR; Gwaltney SL
J Med Chem; 2011 Jan; 54(2):510-24. PubMed ID: 21186796
[TBL] [Abstract][Full Text] [Related]
17. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
18. Structure based virtual screening of MDPI database: discovery of structurally diverse and novel DPP-IV inhibitors.
Tanwar O; Tanwar L; Shaquiquzzaman M; Alam MM; Akhter M
Bioorg Med Chem Lett; 2014 Aug; 24(15):3447-51. PubMed ID: 24948564
[TBL] [Abstract][Full Text] [Related]
19. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
[TBL] [Abstract][Full Text] [Related]
20. Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Mattei P; Boehringer M; Di Giorgio P; Fischer H; Hennig M; Huwyler J; Koçer B; Kuhn B; Loeffler BM; Macdonald A; Narquizian R; Rauber E; Sebokova E; Sprecher U
Bioorg Med Chem Lett; 2010 Feb; 20(3):1109-13. PubMed ID: 20031405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
